Melanoma March 2016 is launched

2 February 2016
Melanoma Institute Australia (MIA) officially launched the 2016 ‘Melanoma March’ initiative in Sydney today.
The launch event held at the Sofitel Sydney Wentworth revealed plans for the new project that will receive funds from this year's Melanoma March campaign. Channel 7's Dr. Andrew Rochford hosted the event, with MIA"s new CEO Carole Renouf helping to get the campaign off to a flying start. Melanoma patient and author of Dear Melanoma Emma Betts also spoke passionately about the importance of research.
Professor Graham Mann, Research Director at MIA, explained how the Melanoma March campaign provides critical funding for an ambitious new project that will ultimately transform the way patients are treated by shining a research light on melanoma care.
Participating melanoma centres around the country will link databases, for the first time bringing together the key information about the treatment of their patients on a national scale. At present melanoma is only recorded by national cancer registries at the time it is initially diagnosed. Data suitable for research about the patients’ treatment and progress is currently only collected in a few specialist centres. This project seeks to expand this substantially and facilitate the appropriate combination of this invaluable information to provided new insights into treatment responses, especially with the less common forms of melanoma where our aggregated national experience will be so informative.
The world-leading ‘Big Data for Melanoma’ project will feature an online platform designed to engage with melanoma care, wherever it takes place.
“With melanoma cases still rising, it’s critical we find ways to keep improving the quality of care. Part of this challenge is to understand the real-world situation of melanoma across the country. This sort of clinical research register has not been attempted before in melanoma. It’s ultimately about improving patient care and saving lives,” MIA’s Research Director Professor Graham Mann said.
During the launch, MIA also updated progress on world-first research into treatment for melanoma brain metastases funded by money raised during the 2014 Melanoma March.
The ground-breaking ‘ABC Trial’, supported by Australia and New Zealand Melanoma Trials Group (ANZMTG), is comparing the use of various immunotherapies in patients with melanoma that has spread to their brain. Running since 2014, the study is showing promising early findings. Patients who once were given just months to live are now surviving longer than a year.
“It’s only early days, but so far we are seeing a tripling of life expectancy for some patients with melanoma that has spread to the brain. There are also added benefits because this kind of work is a world first. Everything we are using is unique – we’re developing new techniques to investigate and learn from the patients’ blood and tumour samples, together with much more advanced brain imaging, which is allowing us to stay at the forefront of research," MIA's Deputy Director Associate Professor Jonathan Stretch said.
Melanoma March events will be hosted in these 24 locations nationally from February 27–April 10, 2016:
VIC: Melbourne
ACT: Canberra
QLD: Bribie Island, Brisbane, Cairns, Coolangatta, Townsville
SA: Adelaide, Port Lincoln
NT: Darwin
WA: Bunbury, Karratha, Perth CBD, Rockingham
NSW: Bathurst, Bonny Hills, Forster Tuncurry, Gosford, Manly, Picton, Wagga Wagga, Western Sydney, Wollongong
TAS: Devonport.
For more information about Melanoma March please visit: www.melanomamarch.org.au.

A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Professor Georgina Long hands on baton of SMR Presidency
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.

City2Surf 2020
Join in the fun of the virtual event, and together we can run over melanoma!

Top melanoma experts at MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Top melanoma experts from MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Melanoma Supportive Care Needs research study.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Research reveals long-term benefit of adjuvant therapy for Stage III melanoma

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

New online melanoma risk calculators critical to saving lives
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Professor Richard Scolyer receives University of Sydney Alumni Award.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Uniting together despite the distance
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Important Update: Masks required at Poche Centre
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.